DeepDrugDiscovery unveiled an AI-driven screening platform designed to identify autophagy enhancers that can cross the blood-brain barrier and target Alzheimer’s disease pathology. The report frames the platform as addressing a core drug-discovery bottleneck: raising brain autophagy without triggering widespread side effects. The approach centers on BBB permeability-aware discovery, aiming to deliver candidate compounds earlier in the pipeline—positioning autophagy modulation as a tractable strategy for neurodegenerative disease development.